

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001802897
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer BioNTech SE
SEC File Number 001-39081
Address of Issuer An der Goldgrube 12
Mainz
GERMANY
55131
Phone 49613190840
Name of Person for Whose Account the Securities are To Be Sold ATHOS KG

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer 10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares representing ordinary shares, no par value per share	J.P. Morgan Securities LLC 390 Madison Avenue - 6th Floor New York NY 10017	37943	4495107	237725735	09/25/2024	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------	---------------------	---------	------------	----------------------	-----------------	---------------------

Transaction	Whom Acquired	a Gift?	Acquired	Acquired
Ordinary Shares, no par value per share	01/05/2018 Private placement BioNTech SE	<input type="checkbox"/>	37943	01/05/2018 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/13/2024	170000	19552584
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/16/2024	590000	72893611
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/17/2024	30162	3754792
AT Impf GmbH Rosenheimer Platz 6 Munich 2M 81669	American Depositary Shares representing ordinary shares, no par value per share	09/18/2024	55605	6934500

144: Remarks and Signature

Remarks The filing of this Form 144 shall not be construed as an admission that the undersigned is an affiliate of the issuer. All ADS to be sold by AT Impf GmbH.

Date of Notice 09/25/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for /s/ Thomas Maier /s/ Stephan Sperber

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)